The study was performed on a cohort of 123 patients diagnosed with r/r MM unresponsive to at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 antibody, and must not have received prior BCMA-directed therapy. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.